Collaboration Announced Between AbbVie and Neomorph to Develop Molecular Glue Degraders for Oncology and Immunology
Collaboration between AbbVie and Neomorph to Develop Novel Molecular Glue Degraders Innovative Partnership In a groundbreaking move, AbbVie and Neomorph, Inc. have joined forces in a collaboration and option-to-license agreement. This partnership will leverage AbbVie’s expertise in oncology and immunology drug development with Neomorph’s leading molecular glue discovery platform. Neomorph will receive an upfront payment…